Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines
In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has ... Read More
Xencor initiates Phase 1 trial of XmAb20717 for advanced solid tumors
Xencor, a prominent biopharmaceutical company based in Monrovia, California, has recently dosed the first patient in a Phase 1 clinical trial named XmAb20717-01 (DUET-2), aimed ... Read More